We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Should You Hold onto Everest Re (RE) Stock Now
Read MoreHide Full Article
Everest Re Group, Ltd. is well-poised to gain from improved net investment income and strong premium growth in the Reinsurance market.
The company has an impressive surprise history, having surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average beat being 31.6%. The Zacks Consensus Estimate for its current-quarter earnings has been revised 4.2% upward in the past 60 days.
Let’s take a look and delve deep into the factors that bode well for the company.
Factors Driving the Company
Everest Re continues to perform well on high premium growth, which, in turn, is boosting top-line growth. Premiums witnessed 6.8% growth in 2019, with which the top line witnessed a CAGR of 9.7% over the past four years (2015-2019). Strong investment income is being driven by higher yields on fixed income portfolio and improved limited partnership income. Investment income rose 11.3% in 2019 and continued to boost the company’s revenues.
Furthermore, Everest Re is well-positioned to benefit from strong premium growth in its reinsurance market. Such premiums usually contribute a major portion to a company’s total gross written premiums and 2019 was no exception. Evidently, it accounted for nearly 70% of total gross written premiums and inched up 2% in 2019 as well. Apart from the adoption of advanced capital and hedging abilities, the company seems to be working to enhance its product portfolio to explore opportunities in the evolving reinsurance market.
Also, Everest Re boasts a robust capital position, which enables it to return value to shareholders via dividend hikes and share buybacks. Last November, it raised the quarterly dividend by 11% and also witnessed a five-year CAGR (2014-2019) of 15.6%. Its current dividend yield is 3.3%, which compares favorably with the industry average of 0.5%. The company also seems to be efficient in utilizing its shareholders’ funds, as indicated by its return on equity of 9.9% being higher than the industry average of 6.4%.
However, shares of this Zacks Rank #3 (Hold) property casualty insurer have lost 31.8% on a year-to-date basis compared with the industry’s decline of 26%. The downside was caused by overall market volatility. Nevertheless, we believe that the company’s strong fundamentals are likely to drive its shares going forward.
All three companies surpassed estimates in the last reported quarters by 6.59%, 33.33% and 28.57%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Here's Why Should You Hold onto Everest Re (RE) Stock Now
Everest Re Group, Ltd. is well-poised to gain from improved net investment income and strong premium growth in the Reinsurance market.
The company has an impressive surprise history, having surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average beat being 31.6%. The Zacks Consensus Estimate for its current-quarter earnings has been revised 4.2% upward in the past 60 days.
Let’s take a look and delve deep into the factors that bode well for the company.
Factors Driving the Company
Everest Re continues to perform well on high premium growth, which, in turn, is boosting top-line growth. Premiums witnessed 6.8% growth in 2019, with which the top line witnessed a CAGR of 9.7% over the past four years (2015-2019). Strong investment income is being driven by higher yields on fixed income portfolio and improved limited partnership income. Investment income rose 11.3% in 2019 and continued to boost the company’s revenues.
Furthermore, Everest Re is well-positioned to benefit from strong premium growth in its reinsurance market. Such premiums usually contribute a major portion to a company’s total gross written premiums and 2019 was no exception. Evidently, it accounted for nearly 70% of total gross written premiums and inched up 2% in 2019 as well. Apart from the adoption of advanced capital and hedging abilities, the company seems to be working to enhance its product portfolio to explore opportunities in the evolving reinsurance market.
Also, Everest Re boasts a robust capital position, which enables it to return value to shareholders via dividend hikes and share buybacks. Last November, it raised the quarterly dividend by 11% and also witnessed a five-year CAGR (2014-2019) of 15.6%. Its current dividend yield is 3.3%, which compares favorably with the industry average of 0.5%. The company also seems to be efficient in utilizing its shareholders’ funds, as indicated by its return on equity of 9.9% being higher than the industry average of 6.4%.
However, shares of this Zacks Rank #3 (Hold) property casualty insurer have lost 31.8% on a year-to-date basis compared with the industry’s decline of 26%. The downside was caused by overall market volatility. Nevertheless, we believe that the company’s strong fundamentals are likely to drive its shares going forward.
Stocks to Consider
Some better-ranked stocks in the same space are CNA Financial Corp. (CNA - Free Report) , First American Financial Corp. (FAF - Free Report) , and RLI Corp. (RLI - Free Report) . While CNA Financial and First American Financial sport a Zacks Rank #1 (Strong Buy), RLI carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
All three companies surpassed estimates in the last reported quarters by 6.59%, 33.33% and 28.57%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>